CA3223211A1 - Methods of using aldosterone synthase inhibitors - Google Patents

Methods of using aldosterone synthase inhibitors Download PDF

Info

Publication number
CA3223211A1
CA3223211A1 CA3223211A CA3223211A CA3223211A1 CA 3223211 A1 CA3223211 A1 CA 3223211A1 CA 3223211 A CA3223211 A CA 3223211A CA 3223211 A CA3223211 A CA 3223211A CA 3223211 A1 CA3223211 A1 CA 3223211A1
Authority
CA
Canada
Prior art keywords
compound
day
dose
visit
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3223211A
Other languages
English (en)
French (fr)
Inventor
Mary BOND
Brian Murphy
Catherine Pearce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincor Pharma Inc
Original Assignee
Cincor Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincor Pharma Inc filed Critical Cincor Pharma Inc
Publication of CA3223211A1 publication Critical patent/CA3223211A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3223211A 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors Pending CA3223211A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163214521P 2021-06-24 2021-06-24
US63/214,521 2021-06-24
US202163290364P 2021-12-16 2021-12-16
US63/290,364 2021-12-16
PCT/US2022/073148 WO2022272300A1 (en) 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
CA3223211A1 true CA3223211A1 (en) 2022-12-29

Family

ID=84545863

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3223211A Pending CA3223211A1 (en) 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors

Country Status (10)

Country Link
US (1) US20240277698A1 (https=)
EP (1) EP4358959A4 (https=)
JP (1) JP2024523559A (https=)
KR (1) KR20240035483A (https=)
AU (2) AU2022299103B2 (https=)
BR (1) BR112023027025A2 (https=)
CA (1) CA3223211A1 (https=)
IL (1) IL309428A (https=)
MX (1) MX2023015121A (https=)
WO (1) WO2022272300A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024310688A1 (en) * 2023-06-29 2026-01-29 AstraZeneca Ireland Limited Crystal form of baxdrostat, and preparation method therefor and use thereof
CN121712504A (zh) * 2023-07-27 2026-03-20 矿物疗法公司 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法
TW202525278A (zh) * 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4777896A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives

Also Published As

Publication number Publication date
EP4358959A1 (en) 2024-05-01
WO2022272300A1 (en) 2022-12-29
AU2022299103A1 (en) 2024-01-25
KR20240035483A (ko) 2024-03-15
IL309428A (en) 2024-02-01
AU2022299103B2 (en) 2025-12-18
US20240277698A1 (en) 2024-08-22
AU2026201954A1 (en) 2026-04-02
JP2024523559A (ja) 2024-06-28
EP4358959A4 (en) 2025-05-14
MX2023015121A (es) 2024-04-16
BR112023027025A2 (pt) 2024-03-12

Similar Documents

Publication Publication Date Title
AU2022299103B2 (en) Methods of using aldosterone synthase inhibitors
JP2010518169A (ja) 心血管疾患の処置のためのラノラジンの使用
JP7402907B2 (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
US20260041679A1 (en) Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat
JP2025111453A (ja) 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン
JP2011511844A (ja) 心血管疾患の処置のためのラノラジンの使用
EP4251164A2 (en) Treatment of raynaud's disease
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
CN117545482A (zh) 使用醛固酮合酶抑制剂的方法
US20070053975A1 (en) Ramipril formulation
WO2023009710A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradol
CN115666564B (zh) 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
AU2023271840A1 (en) Methods of treating focal segmental glomerulosclerosis with atrasentan
AU2024238367A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
CA3256514A1 (en) PHLOROGLUCINOL FORMULATIONS AND METHODS OF USE